shutterstock_1641369829_ascannio

Ascannio / Shutterstock.com

4 November 2020AmericasSarah Morgan

Gilead accuses Floridian clinics of HIV drug fraud

Gilead Sciences has claimed that a group of Florida-based healthcare clinics, pharmacies, and lab testing facilities have “wrongfully captured tens of millions of dollars” through a fraudulent programme.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Campaigners say US govt should have remdesivir patent rights

28 May 2020 The PrEP4All campaign has argued that the US government should own joint patent rights for remdesivir, the Gilead Sciences antiviral which is the only drug approved anywhere for treating COVID-19.

Gilead accused of illegally paying to delay HIV drug competition

22 September 2020 Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.

More on this story

Campaigners say US govt should have remdesivir patent rights

28 May 2020 The PrEP4All campaign has argued that the US government should own joint patent rights for remdesivir, the Gilead Sciences antiviral which is the only drug approved anywhere for treating COVID-19.

Gilead accused of illegally paying to delay HIV drug competition

22 September 2020 Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.

More on this story

Campaigners say US govt should have remdesivir patent rights

28 May 2020 The PrEP4All campaign has argued that the US government should own joint patent rights for remdesivir, the Gilead Sciences antiviral which is the only drug approved anywhere for treating COVID-19.

Gilead accused of illegally paying to delay HIV drug competition

22 September 2020 Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York